[Federal Register: April 30, 1999 (Volume 64, Number 83)]
[Notices]
[Page 23339-23340]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr30ap99-98]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 98E-0846]
Determination of Regulatory Review Period for Purposes of Patent
Extension; ApligrafTM
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) has determined the
regulatory review period for ApligrafTM and is publishing
this notice of that determination as required by law. FDA has made the
determination because of the submission of an application to the
Commissioner of Patents and Trademarks, Department of Commerce, for the
extension of a patent which claims that medical device.
ADDRESSES: Written comments and petitions should be directed to the
Dockets Management Branch (HFA-305), Food and Drug Administration, 5630
Fishers Lane, rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Brian J. Malkin, Office of Health
Affairs (HFY-20), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-827-6620.
SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term
Restoration Act of 1984 (Pub. L. 98-417) and the Generic Animal Drug
and Patent Term Restoration Act (Pub. L. 100-670) generally provide
that a patent may be extended for a period of up to 5 years so long as
the patented item (human drug product, animal drug product, medical
device, food additive, or color additive) was subject to regulatory
review by FDA before the item was marketed. Under these acts, a
product's regulatory review period forms the basis for determining the
amount of extension an applicant may receive.
A regulatory review period consists of two periods of time: A
testing phase and an approval phase. For medical devices, the testing
phase begins with a clinical investigation of the device and runs until
the approval phase begins. The approval phase starts with the initial
submission of an application to market the device and continues until
permission to market the device is granted. Although only a portion of
a regulatory review period may count toward the actual amount of
extension that the Commissioner of Patents and Trademarks may award
(half the testing phase must be subtracted as well as any time that may
have occurred before the patent was issued), FDA's determination of the
length of a regulatory review period for a medical device will include
all of the testing phase and approval phase as specified in 35 U.S.C.
156(g)(3)(B).
FDA recently approved for marketing the medical device
ApligrafTM. ApligrafTM is indicated for use with
standard therapeutic compression in the treatment of uninfected partial
and/or full-thickness skin loss ulcers due to venous insufficiency of
greater than 1 month duration and which have not adequately responded
to conventional ulcer therapy. Subsequent to this approval, the Patent
and Trademark Office received a patent term restoration application for
ApligrafTM (U.S. Patent No. 4,485,096) from Organogenesis,
and the Patent and Trademark Office requested FDA's assistance in
determining this patent's eligibility for patent term restoration. In a
letter dated December 16, 1998, FDA advised the Patent and Trademark
Office that this medical device had undergone a regulatory review
period and that the approval of ApligrafTM represented the
first permitted commercial marketing or use of the product. Shortly
thereafter, the Patent and Trademark Office requested that FDA
determine the product's regulatory review period.
FDA has determined that the applicable regulatory review period for
ApligrafTM is 4,013 days. Of this time, 3,051 days occurred
during the testing phase of the regulatory review period, while 962
days occurred during the approval phase. These periods of time were
derived from the following dates:
1. The date a clinical investigation involving this device was
begun: May 29, 1987. The applicant claims that the investigational
device exemption (IDE) required under section 520(g) of the Federal
Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360j(g)) for human
tests to begin became effective on July 2, 1987. However, FDA records
indicate that the IDE was determined substantially complete for
clinical studies to have begun on May 29, 1987, which represents the
IDE effective date.
2. The date the application was initially submitted with respect to
the device under section 515 of the act (21 U.S.C. 360e): October 4,
1995. FDA has verified the applicant's claim that the
[[Page 23340]]
premarket approval application (PMA) for ApligrafTM (PMA
P950032) was initially submitted on October 4, 1995.
3. The date the application was approved: May 22, 1998. FDA has
verified the applicant's claim that PMA P950032 was approved on May 22,
1998.
This determination of the regulatory review period establishes the
maximum potential length of a patent extension. However, the U.S.
Patent and Trademark Office applies several statutory limitations in
its calculations of the actual period for patent extension. In its
application for patent extension, this applicant seeks 1,826 days of
patent term extension.
Anyone with knowledge that any of the dates as published is
incorrect may, on or before June 29, 1999, submit to the Dockets
Management Branch (address above) written comments and ask for a
redetermination. Furthermore, any interested person may petition FDA,
on or before October 27, 1999, for a determination regarding whether
the applicant for extension acted with due diligence during the
regulatory review period. To meet its burden, the petition must contain
sufficient facts to merit an FDA investigation. (See H. Rept. 857, part
1, 98th Cong., 2d sess., pp. 41-42, 1984.) Petitions should be in the
format specified in 21 CFR 10.30.
Comments and petitions should be submitted to the Dockets
Management Branch (address above) in three copies (except that
individuals may submit single copies) and identified with the docket
number found in brackets in the heading of this document. Comments and
petitions may be seen in the Dockets Management Branch between 9 a.m.
and 4 p.m., Monday through Friday.
Dated: April 20, 1999.
Thomas J. McGinnis,
Deputy Associate Commissioner for Health Affairs.
[FR Doc. 99-10795 Filed 4-29-99; 8:45 am]
BILLING CODE 4160-01-F